Trial · NCT01861912
Arsenic Trioxide TACE and Intravenous Administration in Unresectable Hepatocellular Carcinoma
NCT01861912, Phase 2, Phase 3, Unknown, Guangdong Provincial People's Hospital
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Arsenic Trioxide TACE and Intravenous Administration in Unresectable Hepatocellular Carcinoma. Trials, record NCT01861912. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01861912
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Arsenic Trioxide TACE and Intravenous Administration in Unresectable Hepatocellular Carcinoma
- NCT number
- NCT01861912
- Status
- Unknown
- Phases
- Phase 2, Phase 3
- Enrollment
- 258 participants, estimated
- Lead sponsor
- Guangdong Provincial People's Hospital
- Conditions
- Carcinoma, Hepatocellular
- Interventions
- Arsenic trioxide TACE, Arsenic trioxide intravenous infusion, lipiodol, NaCl solution
- First posted
- 2013-05-24
- Last updated
- 2013-06-05
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Time to Progression | From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years. | Time to progression in our study is defined as the time from a patient's enrollment to the time for disease progression (according to Recist1.1). |
| Secondary | Overall Survival | From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years. | Overall survival in our study is defined as the time from a patient's enrollment to the time for death. |
| Secondary | Quality of Life | From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years. | Quality of life is assessed according to the FACT-Hep questionnaire. |
| Secondary | Safety | From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years. | Safety of our treatment plan will be assessed according to the Common Terminology Criteria for Adverse Events（CTCAE） 3.0 |
| Other | Extrahepatic Metastasis Rate | From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years. | Extrahepatic metastasis rate is defined as the proportion of the extrahepatic metastasis for patients who were absent of extrahepatic metastasis at enrollment. |
| Other | Recurrence Rate | From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years. | Recurrence rate is defined as the proportion of the recurrence in the patients. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01861912
GET https://conductscience.org/api/trials/v1/NCT01861912/registered